ClinicalTrials.gov Requirements Continue To Baffle Firms And Feds Alike
Executive Summary
FDA is continuing to solicit questions about the submissions requirements for ClinicalTrials.gov, even though the formal comments deadline on its initial draft guidance has passed
You may also be interested in...
Pipelines Of Generic Drug Firms May Become More Transparent Under FDAAA
Generic drug firms may soon be forced to disclose their bioequivalence trials under a provision of the FDA Amendments Act that requires companies to post clinical studies on a public Web site.
Pipelines Of Generic Drug Firms May Become More Transparent Under FDAAA
Generic drug firms may soon be forced to disclose their bioequivalence trials under a provision of the FDA Amendments Act that requires companies to post clinical studies on a public Web site.
Clinical Trial Certification: Companies Say IND Submissions Should Be Exempt
Several companies say FDA is requiring clinical trial sponsors to submit too much trial information to a new public database, and they particularly oppose certification of investigational new drug submissions